NVONovo Nordisk A/S
This is the year Novo Nordisk has to prove it can still move the needle in a market that’s grown increasingly allergic to big pharma. The next catalyst — the CagriSema Phase 3 REDEFINE trial results on 2026-10-15 — is the anchor for the bull path, with a modeled target of $47.66 and a bear fallback of $36.51, leaning 50% toward the bull. If the trial delivers, the stock could rally toward $48.70 by the end of Q3, but if the data is mixed or negative, it could fall to $44.55 or worse. The path is clear, the stakes are high, and the outcome will define the next chapter for one of the most powerful names in the pharmaceutical space.
The Read
pricing pressure and margin compression from Event 1, Novo Nordisk's stock rebounded with strong Rx data from Event 2, regulatory wins and pill rollout from Event 3, and solid earnings and volume growth from Events 4 and 5, ultimately leading to a resilient recovery.
The schedule
- Thu15Oct
CagriSema Phase 3 REDEFINE trial results announcement
- Wed4Nov
Q3 2026 Earnings Release and PBM Formula announcement
- Tue1Dec
Phase 3 data readout for Ora and its implications for NVO's pipeline
- Fri15Jan
Eli Lilly Zepbound capacity announcement and its impact on NVO's market position
- Thu4Feb
Q4 2026 Earnings Release and FY2027 Forecast
- Wed5May
- Tue3Aug
Past
- Tue4Aug
Actual outcome: Bull · $47.73 at outcome
Novo Nordisk beat earnings expectations with an EPS of $4.74 versus the estimate of $4.74, signaling stability in its financial performance. The stock rallied due to positive developments around the GLP-1 pill launch, including CEO statements about market differentiation and long-term potential, which reinforced investor confidence despite near-term challenges.
Novo Nordisk reports Q2 results with a critical focus on the early prescription ramp of its newly launched oral Ozempic/Wegovy formulations across 70,000 U.S. pharmacies.
- Sat2May
Actual outcome: Bull · $45.80 at outcome
Novo Nordisk successfully rolled out its oral Ozempic/Wegovy pill across 70,000 U.S. pharmacies, establishing a crucial head start over Eli Lilly in the oral GLP-1 market. Additionally, the FDA proposed excluding the company's weight-loss drugs from the bulk compounding list, providing a significant regulatory win. These positive pipeline and regulatory developments reassured investors and drove the stock toward the bull target, outweighing concerns over pricing pressure and generic approvals in Canada.
- Wed25Mar
Actual outcome: Bull · $40.81 at outcome
Novo Nordisk's prescription data updates revealed resilient demand and strong volume growth for its GLP-1 therapies, easing investor concerns about market share erosion from Eli Lilly's Zepbound. The robust Rx trends confirmed the company's strong competitive positioning in the obesity and diabetes markets, driving the stock's double-digit rally.
- Wed4Feb
Actual outcome: Bear · $37.76 at outcome
Despite an 11.1% EPS beat, Novo Nordisk's stock plummeted as FY2026 guidance confirmed investor fears regarding significant U.S. pricing pressure and margin compression from high manufacturing ramp-up costs. While the Wegovy pill launch showed strong initial volume, the company's defensive shift toward vial presentations to counter Eli Lilly and ongoing legal battles over compounded alternatives signaled a challenging competitive landscape that outweighed the quarterly earnings upside.
